TOKYO, May 25, 2023 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced that it has committed to supporting the 3rd phase of the Global Health Innovative Technology Fund (GHIT Fund), together with a cross-sector group of funding partners. The cross-sector group has committed over US$200 million to the GHIT Fund. Furthermore, we have contributed to the GHIT Fund for three consecutive terms since the inception of the GHIT Fund.

The GHIT Fund launched in 2013 to leverage Japanese expertise and capability for life-saving health innovations, including drugs, vaccines and diagnostics, to combat infectious diseases including tuberculosis, malaria, neglected tropical diseases (NTDs)*1 prevalent in the world’s poorest countries. A public interest corporation registered in Japan, the GHIT Fund is the first international public-private partnership fund (PPP) between the Japanese Government: Ministry of Foreign Affairs, Ministry of Health, Labor and Welfare, private sector, the Bill & Melinda Gates Foundation, the Wellcome and the United Nations Development Programme.

The GHIT Fund has invested about 29.1 billion yen to support approximately 115 projects over the last ten years. The GHIT Fund engages in direct and effective activities, such as the establishment of a public-private partnership mechanism and launching R&D projects utilizing Japanese drug discovery technologies, innovations and investment in diagnostics development.

“Astellas is working to solve issues of Access to Health (ATH) through the GHIT Fund which Astellas has been participating in since the 1st phase of the GHIT Fund and is participating in a GHIT-funded consortium*2 that aims to develop a potential new pediatric treatment option for schistosomiasis in preschool-aged children.” said Naoki Okamura, President and CEO of Astellas. “Astellas is contributing to this development by leveraging our formulation technologies and know-how. In addition, we have contributed to malaria research in collaboration with partners to solve issues of ATH since 2017.”


Click below for a copy of the full press release


Contact the Media Relations team
Communications & Investor Relations
Main phone line for Media: +81-3244-3201 
Business hours (JST)
From Monday to Thursday: 8:45 am to 5:45 pm, Friday: 8:45 am to 4:00 pm
(closed on Saturdays, Sundays, national holidays and company holidays)